<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432080</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1102</org_study_id>
    <nct_id>NCT01432080</nct_id>
  </id_info>
  <brief_title>Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant</brief_title>
  <official_title>Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Canadian Blood and Marrow Transplant Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For many patients with blood cancers, stem cell transplantation from a family member or from
      an unrelated donor remains the only potentially curative option. Unfortunately, up to 40% of
      patients develop chronic lung disease after the transplant, which substantially increases the
      risk of death in the long-term. Currently, patients with transplant-related lung disease are
      treated with some combination of steroids and other immunosuppressant drugs, but only about 1
      out of 5 improve.

      The importance of our study is that the investigators aim to prevent the development of
      transplant-related chronic lung disease in the first place. Because a strong risk factor for
      such chronic lung disease is a prior viral respiratory tract infection, the investigators
      think there is a window of opportunity to intervene. As soon as &quot;cold and flu&quot; symptoms
      start, the investigators will treat patients with a combination of drugs aimed at eliminating
      damaging immune responses triggered by the virus. In the absence of such treatment, the
      investigators believe these lung-damaging immune responses would persist even after the virus
      disappears. Our hope is that preventive treatment might avoid the development of chronic lung
      disease, and this would substantially increase long-term survival in our transplant patients.

      This is a pilot study. Once feasibility is established, the investigators will seek to expand
      this study into a definitive clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not meeting recruitment targets
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 30, 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of new chronic lung disease</measure>
    <time_frame>6 months following diagnosis of the viral respiratory tract infection</time_frame>
    <description>The incidence rate of new non-infectious pulmonary complications within the 6 month follow-up period will be calculated. Non-infectious pulmonary complications include new airflow obstruction, new restrictive lung disease, and new mixed obstruction/restriction as measured by spirometry at study enrolment, 2 and 8 weeks following viral infection, and by full pulmonary function tests at 3 and 6 weeks following viral infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of non-infectious pulmonary complications</measure>
    <time_frame>6 months following the diagnosis of viral respiratory tract infection</time_frame>
    <description>Non-infectious pulmonary complications (NIPCs) include airflow obstruction, restrictive lung disease, and mixed obstruction/restriction as determined by pulmonary function tests. The prevalence of NIPCs will be determined among subjects surviving to 6 months post viral respiratory tract infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term functional impairment as defined by need for supplemental oxygen</measure>
    <time_frame>6 months post viral respiratory tract infection</time_frame>
    <description>The percentage of subjects needing at least 1 month of supplemental oxygen on most days per week, not counting the period of symptomatic viral respiratory tract infection, will be determined in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-perceived long-term functional impairment</measure>
    <time_frame>6 months post viral respiratory tract infection</time_frame>
    <description>A FACT-BMT questionnaire will be administered at baseline and again to subjects surviving 6 months post respiratory tract infection to measure patient-perceived functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clearance of viral infection</measure>
    <time_frame>Every 2 weeks until virus is no longer detectable</time_frame>
    <description>Subjects in whom a respiratory virus is detected will undergo repeat testing every 2 weeks until the virus is no longer detectable. This is an exploratory analysis. The natural history of many of these community-acquired viruses in the transplant population is not known.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression to respiratory failure</measure>
    <time_frame>21 days after enrolment</time_frame>
    <description>This endpoint includes admission to hospital because of documented desaturation, need for supplemental oxygen, and need for mechanical ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bacterial or fungal superinfection</measure>
    <time_frame>Within 21 days after enrolment</time_frame>
    <description>The incidence of secondary bacterial and fungal pneumonias will be compared in the two arms, to verify that the added immunosuppression does not contribute to further infectious complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of various other infectious complications</measure>
    <time_frame>Within 6 months after enrolment</time_frame>
    <description>The incidence of various other infectious complications, specifically including but not limited to CMV reactivations and CMV disease, zoster, and septicemia will be monitored in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival from date of viral respiratory tract infection</measure>
    <time_frame>3 months post enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival from date of viral respiratory tract infection</measure>
    <time_frame>6 months post enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival from date of transplant to end of study follow-up</measure>
    <time_frame>6 months post enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 1 year post-transplant</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>This measure will be applied to the group overall and also analyzed according to subgroups of patients presenting viral respiratory tract infections within 30 days of transplant, 31-100 days of transplant, and 101-365 days of transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death attributable to transplant associated lung disease</measure>
    <time_frame>6 months post enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death from other causes</measure>
    <time_frame>6 months post enrolment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Cryptogenic Organizing Pneumonia</condition>
  <condition>Lung Diseases, Interstitial</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.</description>
    <arm_group_label>SAMS</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Steroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months</description>
    <arm_group_label>SAMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Montelukast 10 mg PO qhs for 3 months</description>
    <arm_group_label>SAMS</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort</intervention_name>
    <description>Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months</description>
    <arm_group_label>SAMS</arm_group_label>
    <other_name>Budesonide</other_name>
    <other_name>Formoterol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allogeneic transplant within the prior 1 year

          -  Age greater than or equal to 18 years

          -  Capable of informed consent

          -  Neutrophil engraftment has occurred

          -  This is the first clinically-recognized episode of viral respiratory tract infection
             after transplant

        Exclusion Criteria:

          -  Proof or high suspicion for bacterial, fungal or any non-viral microorganism causing
             pneumonia

          -  CMV, VZV or HSV pneumonia

          -  Prior diagnosis of a chronic transplant-related non-infectious pulmonary complication
             (ex: BO, COP)

          -  Treating physician believes the risk of systemic steroids is too great

          -  Currently receiving prednisone at or greater than 0.25 mg/kg/day or the equivalent
             dose of another steroid

          -  Currently receiving pentostatin

          -  Mycophenolate initiated de novo or increased within the past 4 weeks

          -  Use of inhaled corticosteroids within the past 2 weeks for at least 1 week

          -  Haploidentical or T-cell depleted graft

          -  Lack of pre-transplant pulmonary function tests

          -  Evidence of a prior symptomatic viral respiratory tract infection following
             transplant, whether treated or not

          -  Allergy or adverse reaction to any of the study drugs

          -  Relapse or progression of the underlying malignancy

          -  Palliative care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth F Krakow, MD,CM, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Cohen, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital (HÃ´pital Maisonneuve-Rosemont)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2011</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth Krakow</investigator_full_name>
    <investigator_title>Fellow in Hematopoietic Cell Transplantation</investigator_title>
  </responsible_party>
  <keyword>Pulmonary disease, chronic obstructive</keyword>
  <keyword>Viral respiratory tract infections</keyword>
  <keyword>Respiratory syncytial viruses</keyword>
  <keyword>Influenza virus A</keyword>
  <keyword>Influenza virus B</keyword>
  <keyword>Transplantation, Allogeneic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Cryptogenic Organizing Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

